Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
BLK reports again on October 16, two days after posting Q3 results that sent the stock down 1.6% on the day, and the setup heading into this second print is materially different from the call-heavy optimism that preceded Wednesday's release.
Options positioning has normalised since the pre-Q3 peak. The put/call ratio has edged back up to 0.74, roughly in line with its 20-day average of 0.74 and a z-score of just -0.11. That is a neutral read: the unusual call demand that defined the pre-Q3 setup has faded, and traders are no longer leaning hard in either direction. The stock has recovered 0.7% on the day to $1,073.79 after Wednesday's sell-off, but it remains flat on the week and down half a percent on the month. The lending market contributes nothing to the debate: short interest holds at 1.3% of the float, borrow availability is effectively unlimited, and the cost to borrow at 0.30% is trivial. There is no short-side pressure worth tracking here.
The analyst story is where the tension sits, and it shifted again on Monday. Morgan Stanley's Mike Cyprys trimmed his Overweight target to $1,468 from $1,479, the second cut from that desk in three weeks. The broader pattern since early October has been target compression without rating changes: TD Cowen raised its Hold target modestly to $1,212, but Evercore ISI, Wells Fargo, UBS, and Barclays all lowered theirs, keeping positive ratings intact. The consensus mean now stands at $1,320, about 23% above the current price. That gap is wide, but the direction of travel on individual targets has been consistently lower. The forward earnings momentum score ranks in the 98th percentile of the ORTEX universe on a 12-month basis, which gives the bulls a structural argument. Bears counter with the margin story: operating margin guidance has been revised down to 43.9% for 2025 and 45.2% for 2026, with G&A expenses running well above prior expectations. Cost growth is the bear case in one line.
Wellington Management added 850,000 shares in its most recent filing, the largest single institutional move in the top-holder list, while Temasek trimmed by 135,000 and Managed Account Advisors cut by 612,000. The net insider picture over the past 90 days shows $22 million of net selling, though the recent transactions on record are all small equity grants to directors rather than discretionary open-market moves. Wikipedia attention for BLK is running nearly two standard deviations above its own 90-day history, a sign of elevated retail interest heading into the second consecutive earnings event this week.
Thursday's print will test whether the margin compression the Street has been pre-emptively pricing in through lower targets is worse or better than feared, and whether AUM flows in the quarter can offset the cost headwinds that have driven the consistent post-earnings selling pattern.
See the live data behind this article on ORTEX.
Open BLK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
